BLLN vs CAI
BLLN: BillionToOne uses breakthrough single-molecule sequencing technology to detect sparse disease signals in blood with unprecedented precision for prenatal and cancer diagnostics. CAI: Caris Life Sciences delivers precision oncology and molecular profiling solutions that help biopharma companies and physicians make treatment decisions through comprehensive tumor analysis.
Side-by-side fundamentals
| Metric | BLLN | CAI | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $127.98 | $16.09 | |
| Market cap as of 2026-08-01 | $6.4B | $4.5B | |
| P/E as of 2026-08-01 | 252.54 | 133.85 | CAI lower |
| PEG as of 2026-08-01 | n/a | -1.00 | |
| Net margin as of 2026-08-01 | +6.2% | +3.8% | BLLN higher |
| Gross margin as of 2026-08-01 | +69.5% | +68.7% | BLLN higher |
| Operating margin as of 2026-08-01 | +8.2% | +9.8% | CAI higher |
| ROE as of 2026-08-01 | +7.6% | +6.5% | BLLN higher |
| ROA as of 2026-08-01 | +5.1% | +3.2% | BLLN higher |
| Debt / equity as of 2026-08-01 | 0.20 | 0.64 | BLLN lower |
| Revenue growth (YoY) as of 2026-08-01 | -37.0% | +78.8% | CAI higher |
| Revenue CAGR (3y) SEC XBRL | +106.2% | +62.9% | BLLN higher |
| Beta as of 2026-08-01 | 1.01 | 0.32 | |
| 1-year return as of 2026-07-30 close | n/a | -45.5% |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.